Recap: Repare Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Repare Therapeutics (NASDAQ:RPTX) reported Q4 earnings with a significant miss on estimated earnings by -46.0%, posting an EPS of $-0.67 against an estimate of $-0.46. Revenue also saw a decrease, down $5.15 million from the same period last year. This contrasts with the previous quarter where the company beat EPS estimates, which was followed by a 5.0% increase in share price the next day.
February 28, 2024 | 2:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Repare Therapeutics reported a significant miss in Q4 earnings with a -46.0% deviation from estimated EPS and a decrease in revenue compared to last year.
The significant miss in earnings and decrease in revenue for Repare Therapeutics is likely to negatively impact investor sentiment in the short term, especially considering the positive reaction to the previous quarter's earnings beat. Historical performance indicates that earnings reports have a direct impact on stock price movement.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100